Independent Neuro Sales Agencies: Adding an EVD Line Without Conflict

An independent neuro sales agency can add an external ventricular drainage line without channel conflict if it checks three things first: that no current principal sells a competing drainage or catheter product, that territories and house accounts are clearly defined, and that the new agreement spells out exclusivity, training and account ownership in writing.

Where does channel conflict actually come from?

Agencies rarely lose a principal because they added a product. They lose principals when a new line touches something the principal considers its own. In neurosurgery, the overlaps are easy to miss because many manufacturers sell across several categories.

The most common sources of friction are:

• Category overlap: A principal that sells shunts may also sell ventricular catheters, external drainage or intracranial pressure monitoring. Even if the agency carries only the shunts today, the principal may see EVD as its territory.
• Account overlap: Some manufacturers keep large IDNs or academic centers as house accounts, with their own direct reps. An agency that starts selling EVD into one of those accounts can collide with the principal's direct team.
• Territory overlap: If the EVD manufacturer already has another agency or distributor in part of the region, two partners may call on the same neuro-ICU.
• Attention overlap: A principal may not object to the category but may worry that rep time will shift away from its products.

Each of these is manageable. None should be discovered after the contract is signed.

How should an agency audit its line card before adding EVD?

Start with a simple matrix. List every principal down the side and every neurosurgical category across the top: shunt valves, ventricular and peritoneal catheters, external ventricular drainage, lumbar drainage, ICP monitoring, dural grafts, hemostats, cranial fixation. Mark what each principal sells, not only what the agency carries.

Read the non-compete language closely. Some agreements prohibit "competing products" in broad terms that could be read to include any CSF management device. If the wording is unclear, ask the principal before you sign anything new. A short, early conversation is cheaper than a terminated contract.

Which principals usually welcome an EVD line?

Not every principal sees a new line as a threat. A dural graft manufacturer, a cranial fixation company or a hemostat supplier usually has no drainage product and may welcome the extra access an EVD line brings. EVD puts reps in the neuro-ICU, in front of residents and nursing leadership, and on the phone with materials management several times a month. That presence makes it easier to hear about new surgeons, new service lines and upcoming value-analysis reviews that matter to every principal in the bag.

Framing matters. Present the EVD line to existing principals as a reason the agency will be more visible in neurosurgery departments, not as a distraction from their products.

What should the agreement with the EVD manufacturer say?

A clear agreement is the best protection against conflict later. Before signing with any EVD manufacturer, an agency should make sure the following points are written down rather than assumed:

• Territory: States, metropolitan areas or named accounts, described precisely.
• Exclusivity: Whether the agency is exclusive for EVD and related catheters in that territory, and what performance expectations are attached.
• Product scope: Which products are included: for example the EVD-010 Series, the EVD-020 Series, lumbar drainage, and whether the ventricular catheter kit and shunt lines are part of the same agreement or separate.
• House accounts: Any accounts the manufacturer keeps for itself or for another partner.
• Training and support: What clinical training, documents and samples the manufacturer provides, and how quickly technical questions are answered.
• Ordering and logistics: Who holds inventory, how consignment works if offered, and who handles returns.
• Complaints and feedback: How the agency reports a product issue and what the manufacturer does in response.
• Term and exit: Notice periods and what happens to open accounts if the relationship ends.

None of this is unusual. Good manufacturers expect these questions and answer them quickly.

How can an agency keep principals informed without oversharing?

Transparency does not mean sharing pricing or account plans from one principal with another. It means telling each principal, in general terms, what the agency carries and why. A short note that says the agency has added an external drainage line, that it does not overlap with the principal's products, and that it brings more ICU access is usually enough. If a principal does sell external drainage, the conversation has to happen before the new agreement, and the agency may need to choose.

Keep the information walls clean in practice as well. Reps should not discuss one principal's pricing, contract terms or product problems with another, even informally in a hospital corridor.

Is EVD worth the training investment for an agency?

Adding EVD is not the same as adding another implant. The agency needs reps who can support nurses at the bedside, run in-services across shifts and answer workflow questions about leveling, clamping and bag changes. That is an investment of time.

The return is a stocked consumable with repeat use, a daily reason to be in the neuro-ICU, and a natural link to ventricular catheters, shunts and dural grafts. For agencies that already cover neurosurgery and want deeper relationships with care teams, it is often one of the most strategic additions they can make.

DESU supports partners with product information, documentation and training material, drawing on experience with distributors in more than 50 countries. Its EVD-010 system combines a 31 cm ventricular catheter, a 30 cm measuring scale, a 150 ml drip chamber and an 800 ml drainage bag, with standard or orange antibiotic-impregnated catheters. The EVD-020 system works with a ventricular or a lumbar catheter. That breadth lets an agency build one coherent drainage story instead of patching together products from different makers.

What does a conflict-free launch look like in the first 90 days?

Once the agreement is signed and existing principals are informed, the launch itself can be planned to avoid stepping on anyone. A sequence that works for many agencies:

• Weeks 1–2: train every rep who will call on neurosurgery, using the manufacturer's material, and agree on a short list of target accounts that are not house accounts of any principal.
• Weeks 3–4: meet surgeon contacts the agency already knows through other lines, explain the new system and ask who leads EVD practice in their neuro-ICU.
• Weeks 5–8: hold first meetings with nursing leadership and supply chain, share documentation, and agree on whether the hospital wants a formal evaluation.
• Weeks 9–12: support any evaluation with in-services on every shift and collect structured feedback for the value-analysis committee.

Throughout, keep a simple log of which accounts the agency has approached for EVD. If a question about account ownership ever arises, a dated record settles it quickly.

Talk to a DESU product specialist

If your agency covers neurosurgery and you are weighing an external drainage line, talk to DESU before you decide. A product specialist can review the range with you, discuss territory and partnership terms for your market, and outline the training support available. Email sales@desu.tr or reach the team through the contact page.